Is FBLG or LGVN more profitable?

FibroBiologics has a net margin of 0.00% compared to Longeveron's net margin of -1,844.49%. Longeveron's return on equity of -202.41% beat FibroBiologics' return on equity. Company Net Margins Return on Equity Return on Assets FibroBiologics N/A -767.07% -195.56% Longeveron -1,844.49% -202.41% -140.67%

Does the media refer more to FBLG or LGVN?

In the previous week, FibroBiologics had 2 more articles in the media than Longeveron. MarketBeat recorded 3 mentions for FibroBiologics and 1 mentions for Longeveron. Longeveron's average media sentiment score of 0.94 beat FibroBiologics' score of 0.66 indicating that Longeveron is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment FibroBiologics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Longeveron 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer EGRX or FBLG?

FibroBiologics has a consensus target price of $74.00, suggesting a potential upside of 6,815.89%. Given FibroBiologics' stronger consensus rating and higher probable upside, analysts plainly believe FibroBiologics is more favorable than Eagle Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Eagle Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 FibroBiologics 1 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is EGRX or FBLG more profitable?

Eagle Pharmaceuticals' return on equity of 0.00% beat FibroBiologics' return on equity. Company Net Margins Return on Equity Return on Assets Eagle Pharmaceuticals N/A N/A N/A FibroBiologics N/A -767.07% -195.56%

Which has preferable earnings and valuation, FBLG or JSPR?

FibroBiologics is trading at a lower price-to-earnings ratio than Jasper Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio FibroBiologics N/A N/A -$18.65M -$6.93 N/A Jasper Therapeutics N/A N/A -$75.80M -$3.23 N/A

Is FBLG or JSPR more profitable?

Jasper Therapeutics' return on equity of -613.51% beat FibroBiologics' return on equity. Company Net Margins Return on Equity Return on Assets FibroBiologics N/A -767.07% -195.56% Jasper Therapeutics N/A -613.51% -162.52%

Does the media favor FBLG or JSPR?

In the previous week, FibroBiologics had 1 more articles in the media than Jasper Therapeutics. MarketBeat recorded 3 mentions for FibroBiologics and 2 mentions for Jasper Therapeutics. FibroBiologics' average media sentiment score of 0.66 beat Jasper Therapeutics' score of 0.47 indicating that FibroBiologics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment FibroBiologics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Jasper Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer FBLG or VYNE?

FibroBiologics currently has a consensus price target of $74.00, suggesting a potential upside of 6,815.89%. Given FibroBiologics' stronger consensus rating and higher possible upside, analysts plainly believe FibroBiologics is more favorable than VYNE Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score FibroBiologics 1 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 VYNE Therapeutics 1 Sell rating(s) 3 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.75

Do analysts prefer TPST or FBLG?

FibroBiologics has a consensus target price of $74.00, suggesting a potential upside of 6,815.89%. Given FibroBiologics' stronger consensus rating and higher probable upside, analysts plainly believe FibroBiologics is more favorable than Tempest Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tempest Therapeutics 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 FibroBiologics 1 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has stronger valuation & earnings, TPST or FBLG?

Tempest Therapeutics is trading at a lower price-to-earnings ratio than FibroBiologics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Tempest Therapeutics N/A N/A -$26.26M -$6.01 N/A FibroBiologics N/A N/A -$18.65M -$6.93 N/A

Is TPST or FBLG more profitable?

Tempest Therapeutics' return on equity of -355.61% beat FibroBiologics' return on equity. Company Net Margins Return on Equity Return on Assets Tempest Therapeutics N/A -355.61% -121.21% FibroBiologics N/A -767.07% -195.56%

Does the media prefer TPST or FBLG?

In the previous week, Tempest Therapeutics had 2 more articles in the media than FibroBiologics. MarketBeat recorded 5 mentions for Tempest Therapeutics and 3 mentions for FibroBiologics. Tempest Therapeutics' average media sentiment score of 0.71 beat FibroBiologics' score of 0.66 indicating that Tempest Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tempest Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive FibroBiologics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

FibroBiologics (FBLG) Competitors

$1.07 0.00 (0.00%)

Closing price 06/4/2026 04:00 PM Eastern

Extended Trading

$1.03 -0.04 (-3.74%)

As of 06/4/2026 07:44 PM Eastern

Compare

FBLG vs. LGVN, EGRX, JSPR, VYNE, and TPST

Should you buy FibroBiologics stock or one of its competitors? MarketBeat compares FibroBiologics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with FibroBiologics include Longeveron (LGVN), Eagle Pharmaceuticals (EGRX), Jasper Therapeutics (JSPR), VYNE Therapeutics (VYNE), and Tempest Therapeutics (TPST). These companies are all part of the "pharmaceutical products" industry.

How does FibroBiologics compare to Longeveron?

FibroBiologics (NASDAQ:FBLG) and Longeveron (NASDAQ:LGVN) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, dividends, earnings, valuation, institutional ownership, media sentiment and risk.

FibroBiologics has higher earnings, but lower revenue than Longeveron. Longeveron is trading at a lower price-to-earnings ratio than FibroBiologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
FibroBiologics	N/A	N/A	-$18.65M	-$6.93	N/A
Longeveron	$1.20M	20.77	-$22.70M	-$1.13	N/A

FibroBiologics has a net margin of 0.00% compared to Longeveron's net margin of -1,844.49%. Longeveron's return on equity of -202.41% beat FibroBiologics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
FibroBiologics	N/A	-767.07%	-195.56%
Longeveron	-1,844.49%	-202.41%	-140.67%

FibroBiologics currently has a consensus price target of $74.00, indicating a potential upside of 6,815.89%. Longeveron has a consensus price target of $5.50, indicating a potential upside of 587.50%. Given FibroBiologics' higher probable upside, research analysts clearly believe FibroBiologics is more favorable than Longeveron.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
FibroBiologics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Longeveron	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

10.0% of Longeveron shares are owned by institutional investors. 9.3% of FibroBiologics shares are owned by company insiders. Comparatively, 7.4% of Longeveron shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

FibroBiologics has a beta of 1.13, indicating that its stock price is 13% more volatile than the broader market. Comparatively, Longeveron has a beta of -0.35, indicating that its stock price is 135% less volatile than the broader market.

In the previous week, FibroBiologics had 2 more articles in the media than Longeveron. MarketBeat recorded 3 mentions for FibroBiologics and 1 mentions for Longeveron. Longeveron's average media sentiment score of 0.94 beat FibroBiologics' score of 0.66 indicating that Longeveron is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
FibroBiologics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Longeveron	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Longeveron beats FibroBiologics on 8 of the 15 factors compared between the two stocks.

How does FibroBiologics compare to Eagle Pharmaceuticals?

Eagle Pharmaceuticals (NASDAQ:EGRX) and FibroBiologics (NASDAQ:FBLG) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, media sentiment, institutional ownership, risk, dividends, valuation and earnings.

Eagle Pharmaceuticals' return on equity of 0.00% beat FibroBiologics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eagle Pharmaceuticals	N/A	N/A	N/A
FibroBiologics	N/A	-767.07%	-195.56%

Eagle Pharmaceuticals has a beta of 0.83, indicating that its stock price is 17% less volatile than the broader market. Comparatively, FibroBiologics has a beta of 1.13, indicating that its stock price is 13% more volatile than the broader market.

Eagle Pharmaceuticals has higher revenue and earnings than FibroBiologics. FibroBiologics is trading at a lower price-to-earnings ratio than Eagle Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eagle Pharmaceuticals	$257.55M	0.03	$35.64M	$1.18	0.44
FibroBiologics	N/A	N/A	-$18.65M	-$6.93	N/A

FibroBiologics has a consensus target price of $74.00, suggesting a potential upside of 6,815.89%. Given FibroBiologics' stronger consensus rating and higher probable upside, analysts plainly believe FibroBiologics is more favorable than Eagle Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eagle Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
FibroBiologics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

85.4% of Eagle Pharmaceuticals shares are owned by institutional investors. 28.9% of Eagle Pharmaceuticals shares are owned by insiders. Comparatively, 9.3% of FibroBiologics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, FibroBiologics had 3 more articles in the media than Eagle Pharmaceuticals. MarketBeat recorded 3 mentions for FibroBiologics and 0 mentions for Eagle Pharmaceuticals. FibroBiologics' average media sentiment score of 0.66 beat Eagle Pharmaceuticals' score of 0.00 indicating that FibroBiologics is being referred to more favorably in the news media.

Company	Overall Sentiment
Eagle Pharmaceuticals	Neutral
FibroBiologics	Positive

Summary

Eagle Pharmaceuticals beats FibroBiologics on 8 of the 14 factors compared between the two stocks.

How does FibroBiologics compare to Jasper Therapeutics?

FibroBiologics (NASDAQ:FBLG) and Jasper Therapeutics (NASDAQ:JSPR) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, risk, profitability, dividends, valuation, institutional ownership and earnings.

79.9% of Jasper Therapeutics shares are owned by institutional investors. 9.3% of FibroBiologics shares are owned by insiders. Comparatively, 4.6% of Jasper Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

FibroBiologics presently has a consensus target price of $74.00, suggesting a potential upside of 6,815.89%. Jasper Therapeutics has a consensus target price of $13.14, suggesting a potential upside of 2,630.70%. Given FibroBiologics' higher possible upside, equities research analysts plainly believe FibroBiologics is more favorable than Jasper Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
FibroBiologics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Jasper Therapeutics	1 Sell rating(s)	6 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.33

FibroBiologics is trading at a lower price-to-earnings ratio than Jasper Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
FibroBiologics	N/A	N/A	-$18.65M	-$6.93	N/A
Jasper Therapeutics	N/A	N/A	-$75.80M	-$3.23	N/A

In the previous week, FibroBiologics had 1 more articles in the media than Jasper Therapeutics. MarketBeat recorded 3 mentions for FibroBiologics and 2 mentions for Jasper Therapeutics. FibroBiologics' average media sentiment score of 0.66 beat Jasper Therapeutics' score of 0.47 indicating that FibroBiologics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
FibroBiologics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Jasper Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Jasper Therapeutics' return on equity of -613.51% beat FibroBiologics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
FibroBiologics	N/A	-767.07%	-195.56%
Jasper Therapeutics	N/A	-613.51%	-162.52%

FibroBiologics has a beta of 1.13, indicating that its stock price is 13% more volatile than the broader market. Comparatively, Jasper Therapeutics has a beta of 3, indicating that its stock price is 200% more volatile than the broader market.

Summary

Jasper Therapeutics beats FibroBiologics on 8 of the 13 factors compared between the two stocks.

How does FibroBiologics compare to VYNE Therapeutics?

FibroBiologics (NASDAQ:FBLG) and VYNE Therapeutics (NASDAQ:VYNE) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, earnings, profitability, institutional ownership, dividends and risk.

FibroBiologics has a net margin of 0.00% compared to VYNE Therapeutics' net margin of -4,726.21%. VYNE Therapeutics' return on equity of -70.42% beat FibroBiologics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
FibroBiologics	N/A	-767.07%	-195.56%
VYNE Therapeutics	-4,726.21%	-70.42%	-63.46%

FibroBiologics currently has a consensus price target of $74.00, suggesting a potential upside of 6,815.89%. Given FibroBiologics' stronger consensus rating and higher possible upside, analysts plainly believe FibroBiologics is more favorable than VYNE Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
FibroBiologics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
VYNE Therapeutics	1 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.75

83.8% of VYNE Therapeutics shares are owned by institutional investors. 9.3% of FibroBiologics shares are owned by company insiders. Comparatively, 3.0% of VYNE Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

FibroBiologics has higher earnings, but lower revenue than VYNE Therapeutics. VYNE Therapeutics is trading at a lower price-to-earnings ratio than FibroBiologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
FibroBiologics	N/A	N/A	-$18.65M	-$6.93	N/A
VYNE Therapeutics	$570K	38.91	-$26.48M	-$0.38	N/A

In the previous week, FibroBiologics had 3 more articles in the media than VYNE Therapeutics. MarketBeat recorded 3 mentions for FibroBiologics and 0 mentions for VYNE Therapeutics. VYNE Therapeutics' average media sentiment score of 1.87 beat FibroBiologics' score of 0.66 indicating that VYNE Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
FibroBiologics	Positive
VYNE Therapeutics	Very Positive

FibroBiologics has a beta of 1.13, suggesting that its stock price is 13% more volatile than the broader market. Comparatively, VYNE Therapeutics has a beta of 2, suggesting that its stock price is 100% more volatile than the broader market.

Summary

FibroBiologics beats VYNE Therapeutics on 8 of the 15 factors compared between the two stocks.

How does FibroBiologics compare to Tempest Therapeutics?

Tempest Therapeutics (NASDAQ:TPST) and FibroBiologics (NASDAQ:FBLG) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, analyst recommendations, dividends, media sentiment, institutional ownership, earnings, valuation and profitability.

Tempest Therapeutics is trading at a lower price-to-earnings ratio than FibroBiologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tempest Therapeutics	N/A	N/A	-$26.26M	-$6.01	N/A
FibroBiologics	N/A	N/A	-$18.65M	-$6.93	N/A

22.5% of Tempest Therapeutics shares are held by institutional investors. 6.3% of Tempest Therapeutics shares are held by company insiders. Comparatively, 9.3% of FibroBiologics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, Tempest Therapeutics had 2 more articles in the media than FibroBiologics. MarketBeat recorded 5 mentions for Tempest Therapeutics and 3 mentions for FibroBiologics. Tempest Therapeutics' average media sentiment score of 0.71 beat FibroBiologics' score of 0.66 indicating that Tempest Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tempest Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
FibroBiologics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Tempest Therapeutics' return on equity of -355.61% beat FibroBiologics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tempest Therapeutics	N/A	-355.61%	-121.21%
FibroBiologics	N/A	-767.07%	-195.56%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tempest Therapeutics	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
FibroBiologics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Tempest Therapeutics has a beta of -1.85, indicating that its share price is 285% less volatile than the broader market. Comparatively, FibroBiologics has a beta of 1.13, indicating that its share price is 13% more volatile than the broader market.

Summary

FibroBiologics beats Tempest Therapeutics on 7 of the 13 factors compared between the two stocks.

Get FibroBiologics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding FBLG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

FBLG vs. The Competition

Export

Metric	FibroBiologics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$5.57M	$3.28B	$6.30B	$12.43B
Dividend Yield	N/A	2.37%	2.69%	5.33%
P/E Ratio	-0.15	18.46	24.03	24.35
Price / Sales	N/A	323.50	522.01	113.27
Price / Cash	N/A	111.03	41.39	55.53
Price / Book	0.58	6.77	9.98	6.72
Net Income	-$18.65M	$24.09M	$3.56B	$337.03M
7 Day Performance	-7.76%	-3.20%	-1.01%	-0.13%
1 Month Performance	-19.55%	0.36%	2.23%	3.76%
1 Year Performance	-93.74%	49.44%	29.09%	34.36%

FibroBiologics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
FBLG FibroBiologics	3.4685 of 5 stars	$1.07 flat	$74.00 +6,815.9%	-93.7%	$5.57M	N/A	N/A	10
LGVN Longeveron	2.8917 of 5 stars	$0.76 -1.0%	$5.50 +621.8%	-32.8%	$24.05M	$1.20M	N/A	20
EGRX Eagle Pharmaceuticals	N/A	$0.70 +21.7%	N/A	-75.0%	$23.38M	$257.55M	0.59	100	Gap Down High Trading Volume
JSPR Jasper Therapeutics	2.8663 of 5 stars	$0.53 -1.2%	$13.14 +2,389.2%	-92.0%	$23.21M	N/A	N/A	20	News Coverage High Trading Volume
VYNE VYNE Therapeutics	1.1611 of 5 stars	$0.68 -0.8%	N/A	-32.8%	$22.77M	$454K	N/A	30	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:FBLG) was last updated on 6/5/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

FibroBiologics (FBLG) Competitors

FBLG vs. LGVN, EGRX, JSPR, VYNE, and TPST

How does FibroBiologics compare to Longeveron?

Summary

How does FibroBiologics compare to Eagle Pharmaceuticals?

Summary

How does FibroBiologics compare to Jasper Therapeutics?

Summary

How does FibroBiologics compare to VYNE Therapeutics?

Summary

How does FibroBiologics compare to Tempest Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FBLG vs. The Competition

FibroBiologics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

FibroBiologics (FBLG) Competitors

FBLG vs. LGVN, EGRX, JSPR, VYNE, and TPST

How does FibroBiologics compare to Longeveron?

Which has better valuation and earnings, FBLG or LGVN?

Is FBLG or LGVN more profitable?

Do analysts rate FBLG or LGVN?

Do institutionals and insiders have more ownership in FBLG or LGVN?

Which has more risk & volatility, FBLG or LGVN?

Does the media refer more to FBLG or LGVN?

Summary

How does FibroBiologics compare to Eagle Pharmaceuticals?

Is EGRX or FBLG more profitable?

Which has more risk & volatility, EGRX or FBLG?

Which has stronger valuation and earnings, EGRX or FBLG?

Do analysts prefer EGRX or FBLG?

Do insiders & institutionals hold more shares of EGRX or FBLG?

Does the media favor EGRX or FBLG?

Summary

How does FibroBiologics compare to Jasper Therapeutics?

Do institutionals and insiders hold more shares of FBLG or JSPR?

Do analysts rate FBLG or JSPR?

Which has preferable earnings and valuation, FBLG or JSPR?

Does the media favor FBLG or JSPR?

Is FBLG or JSPR more profitable?

Which has more volatility & risk, FBLG or JSPR?

Summary

How does FibroBiologics compare to VYNE Therapeutics?

Is FBLG or VYNE more profitable?

Do analysts prefer FBLG or VYNE?

Do insiders and institutionals hold more shares of FBLG or VYNE?

Which has higher valuation and earnings, FBLG or VYNE?

Does the media favor FBLG or VYNE?

Which has more volatility and risk, FBLG or VYNE?

Summary

How does FibroBiologics compare to Tempest Therapeutics?

Which has stronger valuation & earnings, TPST or FBLG?

Do institutionals & insiders believe in TPST or FBLG?

Does the media prefer TPST or FBLG?

Is TPST or FBLG more profitable?

Do analysts prefer TPST or FBLG?

Which has more risk & volatility, TPST or FBLG?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FBLG vs. The Competition

FibroBiologics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools